Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

Ophthalmology
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupFrederick L Ferris

Abstract

To describe effects of ranibizumab and bevacizumab when administered monthly or as needed for 2 years and to describe the impact of switching to as-needed treatment after 1 year of monthly treatment. Multicenter, randomized clinical trial. Patients (n = 1107) who were followed up during year 2 among 1185 patients with neovascular age-related macular degeneration who were enrolled in the clinical trial. At enrollment, patients were assigned to 4 treatment groups defined by drug (ranibizumab or bevacizumab) and dosing regimen (monthly or as needed). At 1 year, patients initially assigned to monthly treatment were reassigned randomly to monthly or as-needed treatment, without changing the drug assignment. Mean change in visual acuity. Among patients following the same regimen for 2 years, mean gain in visual acuity was similar for both drugs (bevacizumab-ranibizumab difference, -1.4 letters; 95% confidence interval [CI], -3.7 to 0.8; P = 0.21). Mean gain was greater for monthly than for as-needed treatment (difference, -2.4 letters; 95% CI, -4.8 to -0.1; P = 0.046). The proportion without fluid ranged from 13.9% in the bevacizumab-as-needed group to 45.5% in the ranibizumab monthly group (drug, P = 0.0003; regimen, P < 0.0001). Sw...Continue Reading

References

Oct 6, 2006·The New England Journal of Medicine·David M BrownUNKNOWN ANCHOR Study Group
Nov 20, 2008·JAMA : the Journal of the American Medical Association·Shobha Rani NalluriShenhong Wu
Jul 8, 2009·Nature Reviews. Clinical Oncology·Helen X Chen, Jessica N Cleck
Apr 30, 2011·The New England Journal of Medicine·UNKNOWN CATT Research GroupGlenn J Jaffe

❮ Previous
Next ❯

Citations

Dec 6, 2012·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·T U KrohneF G Holz
Sep 27, 2012·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Peter K KaiserSimon P Kelly
Nov 2, 2012·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Tao LiuWei-hua Li
Feb 23, 2013·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Maher SalehDavid Gaucher
Apr 18, 2013·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Patrizia TschuorRichard Peter Gale
Apr 23, 2013·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Salomon Y CohenRamin Tadayoni
Jul 31, 2013·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Julia LükeSalvatore Grisanti
Apr 30, 2013·International Journal of Clinical Pharmacy·Roberto BanfiGianni Virgili
Nov 26, 2013·Archivos de la Sociedad Española de Oftalmología·J R Azanza Perea, A García Layana
Jul 21, 2012·Eye·A Grzybowski, F J Ascaso
Oct 26, 2013·Eye·U ChakravarthyUNKNOWN AMD Guidelines Group
May 25, 2013·Nature Reviews. Immunology·Jayakrishna AmbatiBradley D Gelfand
Mar 2, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Kathrin I HartmannLingyun Cheng
Aug 2, 2013·Retina·Noemi LoisReena Kumari
Aug 16, 2013·Retina·Alex Rubowitz
Feb 23, 2013·The British Journal of Ophthalmology·Taiichi HikichiShoko Shioya
Dec 5, 2012·Mediators of Inflammation·Francesco ParmeggianiAdolfo Sebastiani
Dec 18, 2013·Investigative Ophthalmology & Visual Science·Salome MurinelloJessica L Teeling
Oct 23, 2013·BMC Ophthalmology·Lan-Hsin ChuangChi-Chun Lai
Mar 5, 2013·Journal of Translational Medicine·Heather MelvilleNady Golestaneh
Mar 26, 2013·Journal of Ophthalmic Inflammation and Infection·Nikolas Js LondonEmmett T Cunningham
Jun 15, 2013·Clinical Interventions in Aging·Angie H C Fong, Timothy Y Y Lai
Aug 31, 2013·Drug Design, Development and Therapy·F SemeraroC Costagliola
Aug 23, 2012·Therapeutics and Clinical Risk Management·Youxin Chen, Fei Han
May 20, 2014·The British Journal of Ophthalmology·Rish P Singh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.